<DOC>
	<DOCNO>NCT01388621</DOCNO>
	<brief_summary>The purpose trial estimate therapeutic efficacy experimental target regimen include EGFR antibody panitumumab ( combination carboplatin either pegylated liposomal doxorubicin gemcitabine ) relation respective standard combination patient KRAS wildtype platinum-sensitive recurrent ovarian cancer . It expect progression free survival rate 12 month improve targeted regimen .</brief_summary>
	<brief_title>Carboplatin-based Chemotherapy With Without Panitumumab Platinum-sensitive Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Female patient pretreated epithelial ovarian cancer , primary peritoneal carcinomatosis fallopian tube cancer histological confirmation tumor Wildtype kras status Patients must pretreated platinumsensitive ovarian cancer recurrence 6 month completion platinumcontaining regimen Presence least one measurable nonmeasurable disease ( e.g . malignant ascites ) follow RECIST criterion radiologic evaluation OR histological confirmation recurrence biopsy . The presence nonmeasurable lesion require addition 2fold increase CA125 elevation normal lab value ( confirm two measurement ) . No 2 prior treatment regimens epithelial cancer Age &gt; 18 year . ECOG Performance Status 0 1 Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dl Leukocyte count &gt; 3.000/mm3 ; absolute neutrophil count ( ANC ) &gt; 1.500/mm3 Platelet count ≥ 100.000/μl Total bilirubin &lt; 1,0 time upper limit normal ALT AST &lt; 2,5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement cancer ) Alkaline phosphatase &lt; 4 x ULN PTINR/PTT &lt; 1.5 x upper limit normal [ Patients therapeutically anticoagulated agent coumarin heparin allow participate provide prior evidence underlie abnormality parameter exist . ] Serum creatinine &lt; 1.5 x upper limit normal creatinine clearance &gt; 50 ml/min . Magnesium ≥ low limit normal ; calcium ≥ low limit normal Signed date informed consent start specific protocol procedure . Clinically significant cardiovascular disease ( incl . myocardial infarction , unstable angina , symptomatic congestive heart failure , serious uncontrolled cardiac arrhythmia ) ≤ 1 year enrolment . History interstitial lung disease , e.g . pneumonitis pulmonary fibrosis evidence interstitial lung disease baseline chest CT scan . History HIV infection chronic hepatitis B C Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) Preexisting neuropathy &gt; grade 1 ( NCI CTCAE ) , except loss tendon reflex Prior radiological clinical evidence CNS metastases include previously treat , resect , asymptomatic brain lesion leptomeningeal involvement head CT scan MRI Patients seizure disorder require medication ( steroids antiepileptic ) History organ allograft Patients evidence history bleed diathesis Patients undergoing renal dialysis Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis &amp; T1 ] cancer curatively treat &gt; 3 year prior study entry . Patients close institution accord authority court decision Any condition unstable could jeopardize safety patient compliance study Excluded therapy medication , previous concomitant : Anticancer chemotherapy within 4 week prior study entry . Prior antiEGFR therapy Radiotherapy study within 4 week start study drug . ( Palliative radiotherapy nontarget lesion allow ) prior radiotherapy &gt; 25 % bone marrow Major surgery within 4 week start study Autologous bone marrow transplant stem cell rescue within 12 month study Investigational drug therapy outside trial within 4 week study entry Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>ovarian cancer</keyword>
	<keyword>fallopian cancer</keyword>
	<keyword>recurrent</keyword>
	<keyword>platinum-sensitive</keyword>
	<keyword>KRAS-Wildtype</keyword>
</DOC>